Literature DB >> 15791833

Carboxyl terminus truncated human papillomavirus type 58 L1 protein maintains its bioactivity and ability to form virus-like particles.

Wensheng Li1, Hongli Liu, Jin Zheng, Hongwei Chen, Jun Yang, Lixiu Wang, Xiaofei Yan, Yili Wang, Lüsheng Si.   

Abstract

To prepare carboxyl terminus truncated human papillomavirus type 58 L1 (HPV58L1) protein and evaluate its ability to form virus-like particles, the baculovirus and Sf-9 insect cells was used to express HPV58L1 protein, and pFastBac-Htb containing HPV58L1 gene sequence of carboxyl terminus truncation was generated. Then Sf-9 cells were infected with recombinant baculovirus. After being cultured, the post-infected cells expressing--HPV58L1 protein were harvested and analyzed by SDS-PAGE and Western blot. The ProBond purification system was used for protein purification. The bio-activity of purified protein was identified by mouse erythrocyte hemagglutination assay, and the VLP formation was examined with transmission electron microscope. Our results showed that the recombinant baculovirus was generated and the Sf-9 cells was infected with the recombinant baculovirus, and after collecting, total cellular proteins were extracted. Truncated HPV58L1 protein with MW 58KD was revealed by SDS-PAGE and confirmed by Western blot. The purified L1 proteins under native condition could cause mouse erythrocytes to agglutinate and form VLP. It is concluded that HPV58L1 protein with carboxyl terminus truncation could be efficiently expressed. In baculovirus Sf-9 cells expression system, the purified protein could self-assemble into virions in vitro, and induce agglutination of mouse erythrocytes, indicating that carboxyl terminus truncation does not interfere with the bioactivity of HPV58L1 protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15791833     DOI: 10.1007/BF02911347

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  6 in total

Review 1.  Human papillomaviruses and cervical cancer.

Authors:  D J McCance
Journal:  J Med Microbiol       Date:  1998-05       Impact factor: 2.472

2.  Chimeric papillomavirus-like particles.

Authors:  M Müller; J Zhou; T D Reed; C Rittmüller; A Burger; J Gabelsberger; J Braspenning; L Gissmann
Journal:  Virology       Date:  1997-07-21       Impact factor: 3.616

3.  Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein.

Authors:  J Zhou; J Doorbar; X Y Sun; L V Crawford; C S McLean; I H Frazer
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

Review 5.  Human papillomavirus molecular biology and pathogenesis.

Authors:  G Sanclemente; D K Gill
Journal:  J Eur Acad Dermatol Venereol       Date:  2002-05       Impact factor: 6.166

6.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.